"Should Every Breast Lump Be Removed With 'Mammotome'?... Accurate Diagnosis Must Come First, Not Automatic Excision"
Korean Breast Cancer Society and Surgeons' Association Issue Korea-Specific VAE Guidelines
Principle of Implementation After Accurate Tissue Diagnosis
Selective Application Based on Patient and Lesion Characteristics
Vacuum-Assisted Excision (VAE) of breast lesions, commonly known as "Mammotome," is frequently performed for diagnosing breast cancer and removing benign tumors. However, experts have pointed out that VAE should be selectively applied depending on the type of lesion and its malignancy risk.
The Korean Breast Cancer Society and the Korean Society of Breast and Endocrine Surgeons announced on August 20 that they have prepared the first Korean clinical consensus-based guidelines for VAE. According to the guidelines, rather than removing all breast lesions with VAE, clinicians should verify the consistency of biopsy, imaging, and pathology results, and then determine whether to proceed with the procedure based on patient and lesion characteristics.
VAE, often referred to as "Mammotome," has gained widespread use in clinical practice due to its advantage of enabling tissue sampling or removal of small benign lesions through minimal incision. It allows for minimally invasive removal of breast lesions under image guidance using a vacuum-assisted device. From the patient’s perspective, this procedure is also preferred due to relatively less scarring and surgical burden. However, as this procedure has become more commonplace, concerns have been raised about overuse, with VAE being performed even on lesions outside its indicated applications.
The guidelines set forth principles for applying VAE based on a pathological classification system in which biopsy results are divided into B1 through B5. For B2 benign lesions with concordant imaging and pathology findings, the fundamental recommendation is follow-up observation rather than additional invasive intervention. B2 lesions with imaging-pathology concordance have an extremely low risk of later being diagnosed as malignant, so removal for oncological reasons is rarely necessary.
However, VAE can be selectively considered if the patient experiences pain, discomfort, palpable mass, cosmetic issues, or if a significant size increase is observed during follow-up. In cases where the patient has been fully informed of the natural course of the lesion, the need for follow-up observation, and the pros and cons of VAE, and still clearly requests removal, this can also be considered. The guidelines specify that a size increase of more than about 20% within six months should be regarded as clinically significant growth.
B3 lesions are those with uncertain malignant potential, meaning they have not been definitively diagnosed as cancer but still carry some risk, and both the risk of malignancy and appropriate treatment strategy may vary significantly by lesion type. Therefore, rather than indiscriminately performing VAE or universally opting for surgery, the guidelines recommend determining the treatment plan by comprehensively evaluating the lesion’s histological characteristics, the presence of atypia, imaging-pathology concordance, lesion extent, and patient clinical characteristics. They also stress the importance of re-evaluating imaging-pathology concordance after the procedure and considering further biopsy or surgical excision, if necessary, as part of appropriate follow-up management.
For B4 lesions suspicious for malignancy, the guidelines prioritize surgical excision for definitive histological diagnosis and treatment planning, and do not recommend VAE as a treatment option. For B5 malignant lesions, such as ductal carcinoma in situ (DCIS) and invasive breast cancer, standard breast cancer treatment principles must be followed, and it is not appropriate to perform VAE as a curative treatment or as a substitute for standard surgery in routine clinical practice.
The societies explained that while some studies have reported the limited applicability of VAE for malignant lesions, the current level of evidence is insufficient to recognize VAE as a standard treatment option in clinical practice. In research contexts, applying VAE may be allowed based on appropriate study design and approval by the institutional review board (IRB), but the societies emphasized that expanding its clinical indications beyond this is not acceptable.
Core needle biopsy prior to VAE is the principle... exceptions strictly limited
It is essential to confirm the histopathological diagnosis of the lesion through core needle biopsy (CNB) or vacuum-assisted biopsy (VAB) before deciding whether to proceed with VAE. Implementing VAE without prior tissue diagnosis is not recommended as a standard clinical pathway.
The guidelines also call for precise documentation of the lesion’s location and size and the procedure’s objective during VAE, as well as the use of appropriate equipment. For B3 lesions and in cases where further surgery may be anticipated, placement of a tissue marker should be considered, and after the procedure, imaging should be used to confirm the extent of lesion removal and possible residual lesions.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Korean Breast Cancer Society emphasized, “VAE is a useful treatment option that can remove breast lesions minimally invasively in carefully selected patients, but it is not a procedure to remove all lesions. It is important to apply this approach selectively based on accurate diagnosis and patient and lesion characteristics, while ensuring patient safety from pre-procedure evaluation through to post-procedure management.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.